CAS 248594-19-6
:Erlotinib mesylate
Description:
Erlotinib mesylate is a small molecule inhibitor primarily used in the treatment of non-small cell lung cancer and pancreatic cancer. It functions as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, blocking the signaling pathways that promote tumor growth and proliferation. The mesylate salt form enhances the solubility and stability of the drug, facilitating its absorption and bioavailability. Erlotinib mesylate is typically administered orally and is known for its ability to target specific mutations in the EGFR, making it particularly effective in patients with certain genetic profiles. The compound is characterized by its relatively low molecular weight and specific structural features that allow it to bind effectively to the ATP-binding site of the EGFR. Common side effects associated with its use include skin rash, diarrhea, and potential liver enzyme elevation. As with many targeted therapies, monitoring for adverse effects and assessing treatment response is crucial in clinical settings.
Formula:C22H23N3O4·CH4O3S
InChI:InChI=1S/C22H23N3O4.CH4O3S/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;1-5(2,3)4/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H3,(H,2,3,4)
InChI key:InChIKey=PCBNMUVSOAYYIH-UHFFFAOYSA-N
SMILES:N(C=1C2=C(C=C(OCCOC)C(OCCOC)=C2)N=CN1)C3=CC(C#C)=CC=C3.S(C)(=O)(=O)O
Synonyms:- Erlotinib mesylate
- 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, methanesulfonate (1:1)
- 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monomethanesulfonate
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 2 products.
Erlotinib mesylate
CAS:<p>EGFR tyrosine kinase inhibitor</p>Formula:C23H27N3O7SPurity:Min. 95%Color and Shape:White PowderMolecular weight:489.54 g/molErlotinib mesylate
CAS:<p>Erlotinib: reversible inhibitor binding to ATP site of epidermal growth factor receptor.</p>Formula:C23H27N3O7SPurity:98%Color and Shape:SolidMolecular weight:489.54
